CYBN - Psilocybin in depression: study shows lasting benefit
2023-08-31 12:35:49 ET
More on psychedelic drugmakers
- Compass Pathways: Debt Deal Secured, Cash Runway Extended
- COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript
- Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript
- Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
- COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
- Psychedelic Stocks: Don't Bet On Just 1 Company
- Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch
- Compass Pathways: Explorers Of The Neurological Frontier
- Psychedelic therapy should be done in conjunction with psychotherapy - group
- COMPASS Pathways looks to raise $285M from healthcare investors
- MindMed secures $50 million credit facility with K2 HealthVentures
- MindMed inks licensing deal with Catalent for drug technology
- Watch these psychedelic stocks as sector faces year of 'collapse and consolidation'
- SciSparc to begin testing CBD-based treatment for autism in kids
- Congressional psychedelic therapy caucus applauds FDA draft guidance
- President Biden is ‘very open-minded’ about psychedelics, younger brother says
For further details see:
Psilocybin in depression: study shows lasting benefit